Research from Peking University Cancer Hospital and Institute Yields New Data on Personalized Medicine (Abstract 1752: Comprehensive genomic profiling of advanced breast cancer subtypes: Insights from liquid biopsy analysis and implications for...).
In: Women's Health Weekly, 2024-04-12, S. 444-444
serialPeriodical
Zugriff:
A recent study conducted by researchers at Peking University Cancer Hospital and Institute in Beijing, China, explored the use of liquid biopsy analysis to identify genomic alterations in different subtypes of advanced breast cancer. The study included 214 patients with advanced breast cancer and found that PIK3CA mutations were prevalent across all subtypes, suggesting the potential efficacy of PI3K inhibitors in personalized therapies for breast cancer. The findings provide valuable insights into the genomic landscape of advanced breast cancer and lay the groundwork for personalized therapeutic strategies and biomarker identification. [Extracted from the article]
Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Research from Peking University Cancer Hospital and Institute Yields New Data on Personalized Medicine (Abstract 1752: Comprehensive genomic profiling of advanced breast cancer subtypes: Insights from liquid biopsy analysis and implications for...).
|
---|---|
Zeitschrift: | Women's Health Weekly, 2024-04-12, S. 444-444 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1078-7240 (print) |
Sonstiges: |
|